280 related articles for article (PubMed ID: 18981115)
21. Management of imatinib-resistant CML patients.
Linke R; Dempke W
Onkologie; 2007 Nov; 30(11):574-80. PubMed ID: 17992029
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
23. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
25. Korean Red Ginseng Extract Enhances the Anticancer Effects of Imatinib Mesylate Through Abrogation p38 and STAT5 Activation in KBM-5 Cells.
Jung SY; Kim C; Kim WS; Lee SG; Lee JH; Shim BS; Kim SH; Ahn KS; Ahn KS
Phytother Res; 2015 Jul; 29(7):1062-72. PubMed ID: 25857479
[TBL] [Abstract][Full Text] [Related]
26. New strategies in controlling drug resistance in chronic myeloid leukemia.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
[TBL] [Abstract][Full Text] [Related]
27. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
29. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
Kurzrock R; Talpaz M; Li L; Estrov Z
Leuk Lymphoma; 2006 Aug; 47(8):1651-64. PubMed ID: 16966279
[TBL] [Abstract][Full Text] [Related]
30. WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.
Saitoh A; Narita M; Watanabe N; Tochiki N; Yamahira A; Nakamura T; Kaji M; Masuko M; Furukawa T; Toba K; Fuse I; Aizawa Y; Takahashi M
Med Oncol; 2011 Mar; 28(1):219-30. PubMed ID: 20107936
[TBL] [Abstract][Full Text] [Related]
31. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
32. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
[TBL] [Abstract][Full Text] [Related]
33. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Bocchia M; Gentili S; Abruzzese E; Fanelli A; Iuliano F; Tabilio A; Amabile M; Forconi F; Gozzetti A; Raspadori D; Amadori S; Lauria F
Lancet; 2005 Feb 19-25; 365(9460):657-62. PubMed ID: 15721470
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.
Tanaka A; Nishikawa H; Noguchi S; Sugiyama D; Morikawa H; Takeuchi Y; Ha D; Shigeta N; Kitawaki T; Maeda Y; Saito T; Shinohara Y; Kameoka Y; Iwaisako K; Monma F; Ohishi K; Karbach J; Jäger E; Sawada K; Katayama N; Takahashi N; Sakaguchi S
J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31704808
[TBL] [Abstract][Full Text] [Related]
35. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
[TBL] [Abstract][Full Text] [Related]
36. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
37. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
38. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
39. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy.
Ou W; Thapa RK; Jiang L; Soe ZC; Gautam M; Chang JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2018 Jul; 281():84-96. PubMed ID: 29777794
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
